Traductor

23 March 2012

Scientists Wrest Partial Control of a Memory


Scripps Research Institute scientists and their colleagues have successfully harnessed neurons in mouse brains, allowing them to at least partially control a specific memory. Though just an initial step, the researchers hope such work will eventually lead to better understanding of how memories form in the brain, and possibly even to ways to weaken harmful thoughts for those with conditions such as schizophrenia and post traumatic stress disorder.


The results are reported in the March 23, 2012 issue of the journal Science.
Researchers have known for decades that stimulating various regions of the brain can trigger behaviors and even memories. But understanding the way these brain functions develop and occur normally -- effectively how we become who we are -- has been a much more complex goal.
"The question we're ultimately interested in is: How does the activity of the brain represent the world?" said Scripps Research neuroscientist Mark Mayford, who led the new study. "Understanding all this will help us understand what goes wrong in situations where you have inappropriate perceptions. It can also tell us where the brain changes with learning."
On-Off Switches and a Hybrid Memory
As a first step toward that end, the team set out to manipulate specific memories by inserting two genes into mice. One gene produces receptors that researchers can chemically trigger to activate a neuron. They tied this gene to a natural gene that turns on only in active neurons, such as those involved in a particular memory as it forms, or as the memory is recalled. In other words, this technique allows the researchers to install on-off switches on only the neurons involved in the formation of specific memories.
For the study's main experiment, the team triggered the "on" switch in neurons active as mice were learning about a new environment, Box A, with distinct colors, smells and textures.
Next the team placed the mice in a second distinct environment -- Box B -- after giving them the chemical that would turn on the neurons associated with the memory for Box A. The researchers found the mice behaved as if they were forming a sort of hybrid memory that was part Box A and part Box B. The chemical switch needed to be turned on while the mice were in Box B for them to demonstrate signs of recognition. Alone neither being in Box B nor the chemical switch was effective in producing memory recall.
"We know from studies in both animals and humans that memories are not formed in isolation but are built up over years incorporating previously learned information," Mayford said. "This study suggests that one way the brain performs this feat is to use the activity pattern of nerve cells from old memories and merge this with the activity produced during a new learning session."
Future Manipulation of the Past
The team is now making progress toward more precise control that will allow the scientists to turn one memory on and off at will so effectively that a mouse will in fact perceive itself to be in Box A when it's in Box B.
Once the processes are better understood, Mayford has ideas about how researchers might eventually target the perception process through drug treatment to deal with certain mental diseases such as schizophrenia and post traumatic stress disorder. With such problems, patients' brains are producing false perceptions or disabling fears. But drug treatments might target the neurons involved when a patient thinks about such fear, to turn off the neurons involved and interfere with the disruptive thought patterns.
In addition to Mayford, other authors of the paper, "Generation of a Synthetic Memory Trace," are Aleena Garner, Sang Youl Hwang, and Karsten Baumgaertel from Scripps Research, David Rowland and Cliff Kentros from the University of Oregon, Eugene, and Bryan Roth from the University of North Carolina (UNC), Chapel Hill.
This work is supported by the National Institute of Mental Health, the National Institute on Drug Abuse, the California Institute for Regenerative Medicine, and the Michael Hooker Distinguished Chair in Pharmacology at UNC.

**Published in "SCIENCE DAILY"

El modelo del cáncer cervical no vale para tumores de ano



En los últimos 20 años, el cáncer de cuello de útero se ha convertido en uno de los mejor conocidos por los oncólogos: Un virus de transmisión sexual se instala en los tejidos genitales y, si la infección no remite por sí sola, al cabo de los años es capaz de ir generando cambios premalignos en las células que desembocan en un cáncer. Sin embargo, pese a que el mismo virus está implicado también en la aparición de cáncer anal en varones, la historia natural de esta enfermedad no se conoce con tanto detalle.
Prueba de ello es el último estudio que se acaba de publicar en la revista 'The Lancet Oncology', en el que se acaba de demostrar que las lesiones premalignas en el ano no progresan hacia el cáncer con tanta frecuencia como en el caso de las mujeres. "La gran capacidad de replicación de las células en el cuello del útero permite que el virus se reproduzca rápidamente, lo que no ocurre tan fácilmente en otras localizaciones como el pene, el ano o la cavidad orofaríngea", explica a ELMUNDO.es el doctor Xavier Castellsagué, del Instituto Catalán de Oncología (ICO).
La infección por el virus del papiloma humano, que se transmite por vía sexual, está detrás del 80% de los tumores que se originan en el ano (casi en el 100% de tumores cervicales y aproximadamente el 40% en el caso de cáncer de vulva y pene). Y entre la población con más riesgo de desarrollar la enfermedad destacan las mujeres que ya han tenido un tumor cervical, los varones que mantienen relaciones sexuales con otros hombres (que tienen 20 veces más riesgo que los heterosexuales) o los individuos con VIH.

Hacia una citología del ano

Teniendo como modelo la citología, que ha permitido reducir de manera importante la incidencia de cáncer de cuello de útero (gracias a que detecta y extirpa a tiempo las lesiones premalignas), son muchas las voces que han pedido un programa de diagnóstico precoz similar para identificar a tiempo el cáncer anal, sobre todo en dichos grupos de riesgo.
Sin embargo, el trabajo que acaba de publicar Andrew Grulich, de la universidad australiana de Nueva Gales del Sur, muestra que tal vez falten mimbres para ello. Porque después de analizar 53 estudios sobre esta materia, los australianos han descubierto que las lesiones anales premalignas progresan hacia cáncer con mucha menor frecuencia que en el tejido genital femenino.
Concretamente, si una de cada 80 neoplasias de alto grado (lesiones pretumorales) se convierte en un tumor de cérvix; esto sólo ocurre en uno de cada 600 varones homosexuales con VIH, y apenas uno de cada 4.000 sin están libres del virus del sida. "Si hubiese la misma progresión que en mujeres, tendríamos una tasa de cáncer anal mucho más elevada [en España afecta sólo a una de cada 100.000 personas]", señala en la misma línea Castellsagué.
A pesar de ello, su colega el doctor Albert Pahisa, jefe de Infecciosas en el Hospital Vall d'Hebron de Barcelona, es un firme defensor de la detección precoz del cáncer anal en pacientes de riesgo. "Todos los varones homosexuales, seropositivos, deberían hacerse un análisis de recto en busca de lesiones premalignas", apunta. Y aunque es cierto que muchas de ellas nunca progresarían hacia cáncer, Pahisa recuerda que el tratamiento local es tan sencillo ("aplicando calor con un bisturí eléctrico") que en este caso se cumple la máxima del 'más vale prevenir que curar'. "Los resultados son tan espectaculares, con nula morbilidad para el paciente", prosigue, "que incluso debería extenderse a los hombres que mantienen relaciones con hombres, pese a que sean VIH negativos, a partir de los 40 años".

Historia natural de la enfermedad

El artículo australiano subraya que aún quedan lagunas por estudiar en la historia natural del cáncer anal, y apuestan por seguir buscando "marcadores que nos ayuden a identificar qué varones con infección por papilomavirus humano con lesiones premalignas están en riesgo de desarrollar un tumor maligno".
Sólo esa identificación de una buena población de riesgo permitirá poner en marcha un programa tan eficaz como lo ha sido en los últimos 20 años la citología, y con resultados paralelos: reducir la incidencia y la mortalidad de los tumores causados por el virus del papiloma.
De hecho, ésa es la idea en la que insiste el autor de un editorial en la misma revista -Nicolas Wentzensen, de los Institutos Nacionales de Salud de EEUU-. "La implementación de un programa de detección precoz del cáncer anal en población de riesgo necesita más datos para que podamos poner en la misma balanza sus beneficios -la prevención del cáncer-, frente a sus potenciales complicaciones -riesgos del procedimiento, falsos positivos, costes económicos...".

**Publicado en "EL MUNDO"

Antioxidant Supplements Seem to Increase Mortality, Review Shows


Previous research on animal and physiological models suggests that antioxidant supplements have beneficial effects that may prolong life. Some observational studies also suggest that antioxidant supplements may prolong life, whereas other observational studies demonstrate neutral or harmful effects. Our Cochrane review from 2008 demonstrated that antioxidant supplements seem nt
The current evidence does not support the use of antioxidant supplements in the general population or in patients with various diseases.
The present systematic review included 78 randomised clinical trials. In total, 296,707 participants were randomised to antioxidant supplements (beta-carotene, vitamin A, vitamin C, vitamin E, and selenium) versus placebo or no intervention. Twenty-six trials included 215,900 healthy participants. Fifty-two trials included 80,807 participants with various diseases in a stable phase (including gastrointestinal, cardiovascular, neurological, ocular, dermatological, rheumatoid, renal, endocrinological, or unspecified diseases). A total of 21,484 of 183,749 participants (11.7%) randomised to antioxidant supplements and 11,479 of 112,958 participants (10.2%) randomised to placebo or no intervention died.
The trials appeared to have enough statistical similarity that they could be combined. When all of the trials were combined, antioxidants may or may not have increased mortality depending on which statistical combination method was employed; the analysis that is typically used when similarity is present demonstrated that antioxidant use did slightly increase mortality (that is, the patients consuming the antioxidants were 1.03 times as likely to die as were the controls). When analyses were done to identify factors that were associated with this finding, the two factors identified were better methodology to prevent bias from being a factor in the trial (trials with 'low risk of bias') and the use of vitamin A. In fact, when the trials with low risks of bias were considered separately, the increased mortality was even more pronounced (1.04 times as likely to die as were the controls).
The potential damage from vitamin A disappeared when only the low risks of bias trials were considered. The increased risk of mortality was associated with beta-carotene and possibly vitamin E and vitamin A, but was not associated with the use of vitamin C or selenium.

**Published in "SCIENCE DAILY"

La exposición a gérmenes nos protege frente a enfermedades alérgicas y autoinmunes a largo plazo.


La exposición a gérmenes nos protege frente a enfermedades alérgicas y autoinmunes a largo plazo.
Confirmado. Exponer a nuestros hijos a gérmenes, virus y bacterias es mejor para ellos. Así lo asegura un trabajo que se publica esta semana en Science y que confirma la famosa «hipótesis de la higiene», que se basa en que esta exposición mejora la inmunidad a largo plazo.

Son muchos los estudios que han sugerido que la exposición a patógenos durante los primeros años de vida determina la sensibilidad ante las enfermedades alérgicas en la edad adulta. Los médicos han sugerido que la «hipótesis de la higiene» puede explicar el aumento mundial en el número de enfermedades alérgicas y autoinmunes en los entornos urbanos.

Sin embargo, no se habían demostrado las bases biológicas de esta hipótesis. Hasta ahora.

-Confirmado
Un equipo de investigadores del Brigham and Women 's Hospital (EE.UU.) presenta la primera evidencia científica que apoya la «hipótesis de la higiene», así como un posible mecanismo.

Los investigadores han estudiado el sistema inmune de un grupo de ratones que nunca había estado expuesto a ningún tipo de patógenos y los compararon con ratones que viven en un ambiente normal, en el que conviven bacterias, gérmenes, etc.

Los expertos vieron que aquellos animales libres de gérmenes tenían una inflamación exacerbada en los pulmones y en colon, similar a la que se produce en enfermedades como el asma y la colitis. Comprobaron que esta exacerbación estaba producido por una hiperactividad de una clase única de células T (células inmunes) que había sido previamente vinculadas a estos trastornos tanto en ratones como en humanos.

Más relevante aún es que los investigadores descubrieron que la exposición de los ratones libres de gérmenes a los patógenos durante sus primeras semanas de vida, pero no en la vida adulta, provocaba una normalización de su sistema inmunológico y de prevención ante futuras enfermedades. Y, tal y como señala la «hipótesis de la higiene», la protección proporcionada por la exposición infantil a los patógenos era de larga duración.

«Estos estudios -señala Richard Blumberg- muestran la importancia en el desarrollo del acondicionamiento inmune». Además, explica el coordinador del trabajo, el conocimiento de un posible mecanismo permitirá identificar los factores microbianos que inciden en la protección contra las enfermedades alérgicas y autoinmunes a largo plazo.

**Publicado en "ABC SALUD"

Stanford researchers boost potency, reduce side effects of IL-2 protein used to treat cancer


The protein, known as interleukin-2 or IL-2, is a master regulator of the immune system. It acts as a growth factor for many different kinds of immune cells, including an all-important class called T cells. These cells can both recognize and organize attacks against pathogens or tumors.
IL-2 stimulates T cells' proliferation in response to these threats. That makes it a potent anti-cancer drug. When injected into a patient, it spurs fierce anti-tumor activity.
"In a substantial subset -- about 7 percent -- of patients with advanced metastatic melanomas or kidney cancers, IL-2 treatment actually cures the disease," said Christopher Garcia, professor of molecular and cellular physiology and of structural biology and the study's senior author. That's an impressive result, considering the failure of most treatments at such a late stage of cancer.
IL-2 is also used off-label for various other cancers and a wide range of other indications including HIV. But its use is restricted because it can cause severe toxic side effects such as difficulty in breathing due to pulmonary edema, or swelling of the lung, caused by the buildup of fluid in that organ. This in turn is the result of leakage from the copious capillaries that permeate lung tissue, the better to carry away oxygenated blood to distant tissues.
"The cells that cause these toxic effects appear to express different levels and types of IL-2 receptors than do the cells that produce the therapeutic effects," Garcia said. The various classes of immune cells activated by IL-2 have their own characteristic receptor complexes for the protein. Accordingly, each different cell type requires a different concentration of IL-2 for its activation, and each responds in its own way.
In 2005, Garcia and his colleagues determined the structure of IL-2, making it possible to visualize its internal features. "We thought we might be able to tilt the balance of therapeutic-to-toxic effects by modifying this protein in a way that preferentially trips off activation of a desired immune-cell type, while minimizing the activation of an unwanted cell type," he said.
For this study, Garcia's group produced a vast variety of mutated versions of the protein, and then, in a test-tube competition, compared the strength of these mutant proteins' binding to a particular cell-surface receptor, a process that is crucial to the T-cell activation needed to treat cancer. The researchers eventually obtained a mutant that Garcia dubbed "Super-2," which had more than 300 times the receptor-binding strength of natural IL-2. In subsequent tests designed to assess Super-2's ability to impede tumor growth, the new molecule outperformed natural IL-2 by a significant margin.
The researchers also tested Super-2 to determine the extent of the side effects it would cause. To do this, they collaborated with a co-author of the paper, Onur Boyman, MD, of University Hospital Zurich in Switzerland, who had previously found that the type of cells in the lung that are responsible for capillary leakage have receptors for IL-2. Boyman developed an assay for IL-2's most dose-limiting side effect, pulmonary edema. This assay compares the weight of lungs from mice treated with a test compound versus lungs that are not thusly treated. The greater the weight difference, the more fluid buildup has occurred.
Boyman and a member of his group, Carsten Krieg, PhD, who is one of four investigators sharing first authorship of the Nature paper, carried out all the animal research used for the study. By this assay, pulmonary edema caused by Super-2 was significantly and substantially less than by natural IL-2.
Others sharing first authorship of the study were Aron Levin, PhD, (now at Technion University in Israel) and Darren Bates, PhD, (now a scientist at Amgen) who were formerly in Garcia's lab, and his MD/PhD student Aaron Ring.
What makes Super-2 so effective, said Garcia, is its altered shape. A T-cell's IL-2 receptor complex consists of three separate protein components sitting on the cell's surface. These receptors, sometimes referred to as alpha, beta and gamma, act in concert: IL-2 must first touch bases with alpha before it can assume the right shape to bind to beta. Typically, T cells that have never been activated in the past have vanishingly small amounts of alpha on their surfaces, and so require high concentrations of IL-2 to get the process started.
But the mutations Garcia's team induced lock Super-2 into a configuration whose optimized shape lets it bind directly to beta, bypassing alpha. The three-dimensional structure of Super-2, together with computer simulations from the laboratory of associate professor of chemistry Vijay Pande, PhD, suggested this was because the mutant form of IL-2 was less "floppy" than the natural form, so that it presented a "tighter" binding surface to the beta receptor. This souped-up form of the protein was several times as potent as the naturally occurring form of IL-2 at slowing tumor growth, as measured by assays employing three different tumor types in culture.

**Source: Stanford University Medical Center

Una universidad alemana persenta un nuevo prototipo de cerebro-computadora, de los que también hay ejemplos en España




La interfaz cerebro computadora es algo así como un cerebro de chips que ayuda al cerebro humano, dañado por cualquier razón. Una tecnología que se basa en la adquisición de ondas cerebrales para luego ser procesadas e interpretadas por una máquina u ordenador. Diversas universidades trabajan en esta combinación de tecnología y técnica. Hoy, en el campus de Wurzburgo (Alemania) han presentado uno de estos dispositivos, que puede ayudar a activar los músculos de parapléjicos.
Tilo Werner, parapléjico tras un accidente, utiliza en la foto que ilustra estas líneas un gorro con electrodos, durante la presentación de un Interfaz Cerebro Computadora.
Los científicos llevan varios años dándole vueltas al control con la mente -y la tecnología- de objetos. Hay proyectos no invasivos, destinados a utilizar por ejemplo una silla de ruedas sin necesidad de emplear las manos, y otros que necesitan un implante de neuroprótesis que convierte al usuario en una suerte de robot.
En España también hay empresas dedicadas a la investigación de interfaces cerebro computador, quizá "el modo más innovador de lograr la mejora cognitiva", según dicen los responsables de BitBrain Technologies.
El Instituto de Biomecánica de Valencia también trabaja en un sistema ambulante con interfaz cerebro-ordenador para suprimir el temblor basado en la estimulación funcional eléctrica (TREMOR). 

Test to improve peanut allergy diagnosis Published


Researchers from the Murdoch Childrens Research Institute and the University of Melbourne have identified a new way to accurately test for peanut allergy. It is hoped the test will be more cost effective and convenient than standard approaches and minimise over-diagnosis of peanut allergy in the community.
Currently, an oral food challenge is the standard for diagnosing peanut allergy, and while an oral food challenge is definitive in diagnosing patients, it is time-consuming, costly and patients risk severe reactions such as anaphylaxis.
The new test researchers have identified uses part of the peanut protein called 'Arah2' and involves a two-step screening process. Researchers found they could perform a blood test, followed by the Arah2 test, which was more accurate and highly predictive than using one of the tests alone. They found the two step testing process reduced the need for oral food challenges by four-fold.
Co-lead researcher, Thanh Dang, a University of Melbourne PhD student based at the Murdoch Childrens Research Institute, said the new test has many benefits.
"By reducing the number of oral food challenges, this helps prevent many peanut allergics undertaking the unnecessary risks involved."
Associate Professor Katie Allen said the new test could reduce the burden on clinicians and the health care system.
"Due to the rapid increase in rates of sensitisation to foods, allergy services are overwhelmed, and food challenge tests might be difficult to access. This method would help alleviate the current strain and demand on clinical allergy services, with the allergy patient waiting times in excess of 18 months in many centres in Australia," she said. Researchers say the test would also help minimise over-diagnosis, and would reduce the number of patients requiring referral to specialist services for confirmation of a food allergy, by using oral food challenges.
Patients would simply need to visit a GP rather than require a referral to a specialist allergy clinic.
"Due to the long wait times for specialist's clinics, many clinicians are faced with the difficult task of having to assess the presence of food allergy based solely on a positive skin prick test or other available tests and must err on the side of caution and accept a diagnosis of 'possible' food allergy in these situations," Dr Allen said
"This approach can lead to over diagnosis of peanut allergy in the community and a potentially unnecessary burden on the health care system," she said.
Diagnosis of peanut allergy is relatively straightforward when there is an obvious history of clinical reaction to peanut ingestion. However, diagnosis can be more complicated in cases in which the clinical history is not clear or in children who have not yet been exposed to a food.
Researchers say the 'Arah2' twostep process can be used in children with high risk of food allergy, such as those with eczema and other food allergies and for those who haven't eaten peanuts but have a strong family history of food allergy.

**Source: University of Melbourne

CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies

Copyright © Noticia de Salud